The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Human Papillomavirus 16 E7 Oncoprotein Attenuates DNA Damage Checkpoint Control by Increasing the Proteolytic Turnover of Claspin
Published version of a preprint
Abstract
The human papillomavirus (HPV) 16 E7 oncoprotein has been reported previously to stimulate DNA damage and to activate host cell DNA damage checkpoints. How HPV-16 E7 maintains proliferation despite activated DNA damage checkpoints is incompletely understood. Here, we provide evidence that cells expressing the HPV-16 E7 oncoprotein can enter mitosis in the presence of DNA damage. We show that this activity of HPV-16 E7 involves attenuation of DNA damage checkpoint control by accelerating the proteolytic turnover of claspin. Claspin mediates the activation of CHK1 by ATR in response to replication stress, and its degradation plays a critical role in DNA damage checkpoint recovery. Expression of a nondegradable mutant of claspin was shown to inhibit mitotic entry in HPV-16 E7–expressing cells. Multiple components of the SCFβ-TrCP–based claspin degradation machinery were found deregulated in the presence of HPV-16 E7, including cullin 1, β-TrCP, Aurora A, and Polo-like kinase-1 (PLK1). In contrast, no difference in the expression level of the claspin deubiquitinating enzyme USP7 was detected. Levels of Aurora A and PLK1 as well as phosphorylated PLK1 at threonine 210, a prerequisite for DNA damage checkpoint recovery, remained detectable following replication stress in HPV-16 E7–expressing cells but not in control cells. In summary, our results suggest that the HPV-16 E7 oncoprotein alleviates DNA damage checkpoint responses and promotes mitotic entry by accelerating claspin degradation through a mechanism that involves deregulation of components of the SCFβ-TrCP–based claspin degradation machinery. [Cancer Res 2009;69(17):7022–9]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“high-risk E7 was shown to target claspin, a key regulator of the ATR-Chk1 pathway that is activated in response to replications stress. HPV-16 E7 also attenuates mitotic checkpoint control by upregulating cellular factors involved in destabilization of claspin—a positive regulator of the mitotic checkpoint; this activity is primarily dependent E7’s inactivation of pRB, as most of the factors inv”
From The Not-So-Good, the Bad and the Ugly: HPV E5, E6 and E7 Oncoproteins in the Orchestration of Carcinogenesis (2021) · cites this paper as [319]
In the citing paper
“Thus, E7-induced accelerated degradation of claspin in G2/M leads cells to initiate checkpoint recovery, even in the presence of DNA damage that could potentially lead to genomic instability [319]”
From The Not-So-Good, the Bad and the Ugly: HPV E5, E6 and E7 Oncoproteins in the Orchestration of Carcinogenesis (2021) · cites this paper as [319]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peschiaroli, A., Dorrello, N. V., Guardavaccaro, D., Venere, M., Halazonetis, T., Sherman, N. E., & Pagano, M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.06.013 · Cited by 289
Polo-like Kinase-1 Controls Proteasome-Dependent Degradation of Claspin during Checkpoint Recovery
Mamely, I., van Vugt, M. A., Smits, V. A., Semple, J. I., Lemmens, B., Perrakis, A., Medema, R. H., & Freire, R. (2006) · Current Biology · doi:10.1016/j.cub.2006.08.026 · Cited by 227
Human Claspin works with BRCA1 to both positively and negatively regulate cell proliferation
Lin, S.-Y., Li, K., Stewart, G. S., & Elledge, S. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401847101 · Cited by 156
USP7 counteracts SCFβTrCP- but not APCCdh1-mediated proteolysis of Claspin
Faustrup, H., Bekker-Jensen, S., Bartek, J., Lukas, J., & Mailand, N. (2009) · The Journal of Cell Biology · doi:10.1083/jcb.200807137 · Cited by 113
Research works printed but not linked: 38
- zur Hausen H. Papillomaviruses in the causation of human cancers—a brief historical account. Virology 2009; 384: 260–5. · DOI · Paper page
- Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002; 89: 213–28. · DOI
- Munger K, Basile JR, Duensing S, et al. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 2001; 20: 7888–98. · DOI
- Jones DL, Alani RM, Munger K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev 1997; 11: 2101–11. · DOI · Paper page
- Funk JO, Waga S, Harry JB, Espling E, Stillman B, Galloway DA. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 1997; 11: 2090–100. · DOI · Paper page
- Zerfass-Thome K, Zwerschke W, Mannhardt B, Tindle R, Botz JW, Jansen-Durr P. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 1996; 13: 2323–30.
- Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 2004; 68: 362–72. · DOI
- Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996; 380: 79–82. · DOI · Paper page
- Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129–36. · DOI · Paper page
- DiMaio D, Liao JB. Human papillomaviruses and cervical cancer. Adv Virus Res 2006; 66: 125–59. · DOI
- Tanaka S, Diffley JF. Deregulated G1-cyclin expression induces genomic instability by preventing efficient pre-RC formation. Genes Dev 2002; 16: 2639–49. · DOI
- Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434: 864–70. · DOI · Paper page
- Ekholm-Reed S, Mendez J, Tedesco D, Zetterberg A, Stillman B, Reed SI. Deregulation of cyclin E in human cells interferes with prereplication complex assembly. J Cell Biol 2004; 165: 789–800. · DOI
- Spardy N, Duensing A, Charles D, et al. The human papillomavirus type 16 E7 oncoprotein activates the Fanconi anemia (FA) pathway and causes accelerated chromosomal instability in FA cells. J Virol 2007; 81: 13265–70. · DOI
- Howlett NG, Taniguchi T, Durkin SG, D'Andrea AD, Glover TW. The Fanconi anemia pathway is required for the DNA replication stress response and for the regulation of common fragile site stability. Hum Mol Genet 2005; 14: 693–701. · DOI
- Liu X, Han S, Baluda MA, Park NH. HPV-16 oncogenes E6 and E7 are mutagenic in normal human oral keratinocytes. Oncogene 1997; 14: 2347–53. · DOI
- Duensing S, Munger K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res 2002; 62: 7075–82.
- Kessis TD, Connolly DC, Hedrick L, Cho KR. Expression of HPV16 E6 or E7 increases integration of foreign DNA. Oncogene 1996; 13: 427–31.
- Song S, Gulliver GA, Lambert PF. Human papillomavirus type 16 E6 and E7 oncogenes abrogate radiation-induced DNA damage responses in vivo through p53-dependent and p53-independent pathways. Proc Natl Acad Sci U S A 1998; 95: 2290–5. · DOI
- Helt AM, Galloway DA. Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes. J Virol 2001; 75: 6737–47. · DOI · Paper page
- O'Connell MJ, Walworth NC, Carr AM. The G2-phase DNA-damage checkpoint. Trends Cell Biol 2000; 10: 296–303. · DOI
- Kumagai A, Dunphy WG. Claspin, a novel protein required for the activation of Chk1 during a DNA replication checkpoint response in Xenopus egg extracts. Mol Cell 2000; 6: 839–49. · DOI · Paper page
- Chini CC, Chen J. Claspin, a regulator of Chk1 in DNA replication stress pathway. DNA Repair (Amst) 2004; 3: 1033–7. · DOI
- Mailand N, Bekker-Jensen S, Bartek J, Lukas J. Destruction of claspin by SCFβTrCP restrains Chk1 activation and facilitates recovery from genotoxic stress. Mol Cell 2006; 23: 307–18. · DOI · Paper page
- Macurek L, Lindqvist A, Lim D, et al. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature 2008; 455: 119–23. · DOI
- Bassermann F, Frescas D, Guardavaccaro D, Busino L, Peschiaroli A, Pagano M. The Cdc14B-Cdh1-1 axis controls the G2 DNA-damage-response checkpoint. Cell 2008; 134: 256–67. · DOI · Paper page
- Zhang D, Zaugg K, Mak TW, Elledge SJ. A role for the deubiquitinating enzyme USP28 in control of the DNA-damage response. Cell 2006; 126: 529–42. · DOI
- Lupardus PJ, Cimprich KA. Checkpoint adaptation; molecular mechanisms uncovered. Cell 2004; 117: 555–6. · DOI
- Yoo HY, Kumagai A, Shevchenko A, Dunphy WG. Adaptation of a DNA replication checkpoint response depends upon inactivation of claspin by the Polo-like kinase. Cell 2004; 117: 575–88. · DOI · Paper page
- Toczyski DP, Galgoczy DJ, Hartwell LH. CDC5 and CKII control adaptation to the yeast DNA damage checkpoint. Cell 1997; 90: 1097–106. · DOI
- Sandell LL, Zakian VA. Loss of a yeast telomere: arrest, recovery, and chromosome loss. Cell 1993; 75: 729–39. · DOI
- Syljuasen RG, Jensen S, Bartek J, Lukas J. Adaptation to the ionizing radiation-induced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Polo-like kinase 1 kinases. Cancer Res 2006; 66: 10253–7. · DOI
- Lindon C, Pines J. Ordered proteolysis in anaphase inactivates Plk1 to contribute to proper mitotic exit in human cells. J Cell Biol 2004; 164: 233–41. · DOI
- Uchiumi T, Longo DL, Ferris DK. Cell cycle regulation of the human polo-like kinase (PLK) promoter. J Biol Chem 1997; 272: 9166–74. · DOI
- Kimura M, Kotani S, Hattori T, et al. Cell cycle-dependent expression and spindle pole localization of a novel human protein kinase, Aik, related to Aurora of Drosophila and yeast Ipl1. J Biol Chem 1997; 272: 13766–71. · DOI
- Iwanaga R, Komori H, Ishida S, et al. Identification of novel E2F1 target genes regulated in cell cycle-dependent and independent manners. Oncogene 2006; 25: 1786–98. · DOI
- He L, Yang H, Ma Y, Pledger WJ, Cress WD, Cheng JQ. Identification of Aurora-A as a direct target of E2F3 during G2-M cell cycle progression. J Biol Chem 2008; 283: 31012–20. · DOI
- Ishida S, Huang E, Zuzan H, et al. Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol Cell Biol 2001; 21: 4684–99. · DOI
Cited by
Basukala, O., & Banks, L. (2021) · Viruses · doi:10.3390/v13101892 · Cited by 137
Metadata
- Authors
- Spardy, N., Covella, K., Cha, E., Hoskins, E. E., Wells, S. I., Duensing, A., & Duensing, S.
- Affiliations
- 1Biochemistry and Molecular Genetics Graduate Program, Departments of
- 4Molecular Virology Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania; and
- 5Division of Hematology and Oncology, Cincinnati's Children's Hospital Medical Center, Cincinnati, Ohio
- 2Pathology and
- 3Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine;
- Venue
- Cancer Research
- Published
- 2009-08-31
- Volume
- 69
- Issue
- 17
- Pages
- 7022-7029
- ISSN
- 0008-5472
- 1538-7445
- PMC
- PMC2737077
- Cited by
- 91
- References
- 4
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review